Hospital stocks rallied after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially cutting prices by 20–70% and saving patients ₹2,500 crore annually. Brokerages said earnings effects may be manageable but warned that hospital margins could face pressure.
Hospital stocks rallied after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially cutting prices by 20–70% and saving patients ₹2,500 crore annually. Brokerages said earnings effects may be manageable but warned that hospital margins could face pressure.
<iframe src="https://hindustansphere.com/embed/cluster/8b5ee731d7b4d74898e3d1dc42a2b3f496b39bbd" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Fortis Healthcare, Apollo Hospitals, Max, Medanta shares rise: Should investors buy after 30% cancer drug price cap?"></iframe>
